Pre-made Andecaliximab benchmark antibody ( Whole mAb, anti-MMP9/MMP-9 therapeutic antibody, Anti-CLG4B/GELB/MANDP2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Andecaliximab biosimilar, Whole mAb, Anti-MMP9/MMP-9 Antibody: Anti-CLG4B/GELB/MANDP2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Andecaliximab (INN; development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.
| Products Name (INN Index) | Pre-Made Andecaliximab biosimilar, Whole mAb, Anti-MMP9/MMP-9 Antibody: Anti-CLG4B/GELB/MANDP2 therapeutic antibody |
|---|---|
| INN Name | Andecaliximab |
| Target | MMP9 |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | 5th9:HL:IM:JN |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Gilead Sciences |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Chronic obstructive pulmonary disease,Crohn's disease,Cystic fibrosis,Rheumatoid arthritis,Ulcerative colitis,Gastric cancer,Solid tumours,Glioblastoma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MMP9/MMP-9 |
| Package |
